Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The REALITY Study1 demonstrates how optimizing the combination of HawkOne™ directional atherectomy and IN.PACT™ Admiral™ drug-coated balloon (DCB) in treating peripheral artery disease (PAD) can help achieve excellent patient outcomes.
The REALITY Study was independently sponsored and conducted by the VIVA Physicians. The study prospectively enrolled 102 participants whose treatment outcomes were independently adjudicated by angiographic and duplex ultrasound core labs and a clinical events committee. The research was funded by Medtronic.
Bilateral calcium [PACSS 3+4]
Average lesion length
Bilateral calcium ≥ 5 cm [PACSS 4]
Chronic total occlusions at baseline
BAILOUT STENT RATE
30-DAY MAJOR
ADVERSE EVENTS‡
12-MONTH PATENCY
Data reported includes patients beyond the follow-up window.
12-MONTH FREEDOM
FROM CD-TLR
Data reported includes patients beyond the follow-up window.
From simple to complex cases, the HawkOne directional atherectomy system offers the versatility physicians need to remove plaque and restore flow.
Learn about HawkOne DeviceThe only DCB proven through 5 years with 75% of patients reintervention-free.2 Now backed by 5-year global study data.3
Learn about IN.PACT Admiral DCBCardioVascular Lifeline
Customer Support
1-763-526-7890
rs.cstechsupport@medtronic.com
Orders
1-763-514-8510
rs.cuvasorders@medtronic.com
24-hour Technical Support
+1-763-514-4000 (worldwide)
™Third party brands are trademarks of their respective owners.
This image is an example of a REALITY Study lesion, it is for illustrative purposes only, and is not representative of an exact lesion from a patient in the study.
Major adverse event (MAE) was defined as flow-limiting dissections (D-F), vessel perforations requiring stenting or stent-grafts, unplanned amputation, intra-procedural distal athero-embolization, and clinically driven TVR.
Rocha-Singh, K. Data presented at VIVA 2020.
Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. June 2019;12(6):e007702.
Zeller T. Data presented at VIVA 2020.